Press Releases

Dec 11, 2017
LONDON , Dec. 11, 2017 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (Nasdaq:GWPH) ("GW" or the “Company”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, announced today the closing of the
Dec 05, 2017
LONDON , Dec. 05, 2017 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (Nasdaq:GWPH) ("GW" or the “Company”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, announced today that it intends to sell,
Nov 22, 2017
- 29th Annual Piper Jaffray Healthcare Conference on November 29, 2017 - - Evercore ISI 2017 Biopharma Catalyst/Deep Dive Conference on November 30, 2017 - LONDON , Nov. 22, 2017 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (Nasdaq:GWPH) ("GW" or "the Company"), a biopharmaceutical company focused on
Oct 30, 2017
LONDON and CARLSBAD, Calif., Oct. 30, 2017 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (Nasdaq:GWPH) ("GW" or "the Company"), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, along with its U.S.
Sep 05, 2017
- Morgan Stanley 15 th Annual Global Healthcare Conference on 13 September -             - Leerink Partners Rare Disease & Immuno-Oncology Roundtable Series on 27 September - LONDON, Sept. 05, 2017 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (Nasdaq:GWPH) ("GW" or "the Company"), a biopharmaceutical